MaxCyte, Inc.
MaxCyte empowers scientists across cell therapy, protein production, gene editing, and cell-based assay development with over 25 years of experience. Their Flow Electroporation® technology and ExPERT platform enable efficient, scalable, and precise engineering of complex cell types, supporting the journey from discovery to commercialization through a partnership-first approach. The company offers a broad range of electroporation systems, consumables, and application-specific solutions to accelerate research and clinical development.
Industries
Nr. of Employees
small (1-50)
Patents
Engineering and delivery of therapeutic compositions of freshly isolated cells
US-11331344-B2
View Details
Engineering and delivery of therapeutic compositions of freshly isolated cells
US-11331344-B2
View DetailsProducts
Scalable electroporation instrument family (static and flow)
A family of electroporation systems that support both static well formats and closed‑bag flow processing to enable consistent transfection from small research volumes through clinical‑scale manufacturing and large‑scale protein production.
Processing assemblies, racks and accessory consumables
Disposable processing assemblies, handling racks and accessory kits available in multiple formats (multi‑well strips, single‑chamber units, closed‑bag flow assemblies) to support throughput, sample handling and closed‑process compatibility.
GMP electroporation buffers and supporting reagents
Electroporation buffer formulations manufactured under cGMP, provided in bottle and sterile bag formats, formulated without animal/human components and tested for sterility and endotoxin to support both open and closed workflows.
Scalable electroporation instrument family (static and flow)
A family of electroporation systems that support both static well formats and closed‑bag flow processing to enable consistent transfection from small research volumes through clinical‑scale manufacturing and large‑scale protein production.
Processing assemblies, racks and accessory consumables
Disposable processing assemblies, handling racks and accessory kits available in multiple formats (multi‑well strips, single‑chamber units, closed‑bag flow assemblies) to support throughput, sample handling and closed‑process compatibility.
GMP electroporation buffers and supporting reagents
Electroporation buffer formulations manufactured under cGMP, provided in bottle and sterile bag formats, formulated without animal/human components and tested for sterility and endotoxin to support both open and closed workflows.
Services
Laboratory assay services that identify and quantify on‑target and off‑target genome editing events using nomination, screening and confirmation sequencing workflows to support candidate selection and regulatory filings.
Consulting services and on‑demand scientific support to optimize electroporation protocols, define scalable workflows, perform process qualification and assist with technology transfer to manufacturing partners.
Laboratory assay services that identify and quantify on‑target and off‑target genome editing events using nomination, screening and confirmation sequencing workflows to support candidate selection and regulatory filings.
Consulting services and on‑demand scientific support to optimize electroporation protocols, define scalable workflows, perform process qualification and assist with technology transfer to manufacturing partners.
Expertise Areas
- Non‑viral cell engineering and electroporation
- Cell therapy manufacturing support (CAR‑T, CAR‑NK, TCR‑T and NK cells)
- CRISPR and multiplex gene‑editing workflows
- Transient protein and antibody expression for rapid bioproduction
Key Technologies
- Non‑viral electroporation (static and flow)
- Closed‑system and multi‑format processing assemblies
- cGMP‑manufactured, animal‑component‑free electroporation buffers
- Ribonucleoprotein (RNP) and large‑plasmid delivery by electroporation
News & Updates
MaxCyte has joined forces with Ori Biotech to enhance the scalability, efficiency, and accessibility of gene-edited cell therapies.
Latest updates and insights from MaxCyte.
A Technology Networks article featuring insights from Dr. Mancini.
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
MaxCyte Minutes Newsletter – Q2 2025
Building the Future of Cell Therapies: Insights From Dr. Andrew Mancini
MaxCyte has joined forces with Ori Biotech to enhance the scalability, efficiency, and accessibility of gene-edited cell therapies.
Latest updates and insights from MaxCyte.
A Technology Networks article featuring insights from Dr. Mancini.